Nesiritide - not verified.
Topol
Eric J
EJ
Case Western Reserve University, Cleveland, USA.
D016907:Adverse Drug Reaction Reporting Systems; D017277:Drug Approval; D016527:Drug Costs; D004345:Drug Industry; D006300:Health Services Misuse / Q000191:economics; D006333:Heart Failure / Q000188:drug therapy* / Q000401:mortality; D006801:Humans; D007262:Infusions, Intravenous; D040541:Marketing; D006278:Medicare; D045283:Natriuretic Agents / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use*; D020097:Natriuretic Peptide, Brain / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use*; D005996:Nitroglycerin / Q000627:therapeutic use; D017063:Outcome Assessment, Health Care / Q000379:methods / Q000592:standards; D011669:Pulmonary Wedge Pressure / Q000187:drug effects; D012107:Research Design; D014481:United States; D014486:United States Food and Drug Administration; D014665:Vasodilator Agents / Q000627:therapeutic use
D045283:Natriuretic Agents; D014665:Vasodilator Agents; D020097:Natriuretic Peptide, Brain; D005996:Nitroglycerin